Chugai’s 1st-Half Sales Excluding Tamiflu Down 0.3% in Japan as Mircera Slumps

July 30, 2012
In its consolidated settlement of accounts for January-June 2012 announced on July 26, Chugai Pharmaceutical’s domestic sales, excluding the anti-influenza virus drug Tamiflu (oseltamivir), fell 0.3% compared to the corresponding period of the previous year to 150.4 billion yen. Sales...read more